Browse by author
Lookup NU author(s): Professor Andrew GenneryORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Nijmegen breakage syndrome (NBS) is characterized by chromosomal instability, radiation hypersensitivity, characteristic facial appearance, immunodeficiency and strong predisposition to lymphoid malignancy. Traditionally, NBS patients have not undergone hematopoietic SCT (HSCT) owing to concerns about increased toxicity. We therefore report on the HSCT experience in NBS patients in Europe. Six patients were transplanted either for resistant or secondary malignancy (four patients) or severe immunodeficiency (two patients). Five patients received reduced-intensity conditioning regimens. After a median follow-up of 2.2 years, five patients are alive and well. One patient who received myeloablative conditioning died from sepsis before engraftment. Acute GVHD grades I-II occurred in three of five patients, mild chronic GVHD in one. All five surviving patients exhibit restored T-cell immunity. The experience in these six patients suggests that HSCT in NBS is feasible, can correct the immunodeficiency and effectively treat malignancy. Acute toxicity seems to be reasonable with reduced-intensity conditioning regimens. Bone Marrow Transplantation (2010) 45, 622-626; doi:10.1038/bmt.2009.207; published online 17 August 2009
Author(s): Albert MH, Gennery AR, Greil J, Cale CM, Kalwak K, Kondratenko I, Mlynarski W, Notheis G, Fuhrer M, Schmid I, Belohradsky BH
Publication type: Article
Publication status: Published
Journal: Bone Marrow Transplantation
Year: 2010
Volume: 45
Issue: 4
Pages: 622-626
Print publication date: 01/04/2010
ISSN (print): 0268-3369
ISSN (electronic): 1476-5365
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/bmt.2009.207
DOI: 10.1038/bmt.2009.207
Altmetrics provided by Altmetric